Multiplexed 'Touch and Tell' Optical Molecular Sensing and Imaging

Lead Research Organisation: University of Edinburgh
Department Name: Sch of Chemistry

Abstract

This project is all about multi-disciplinary collaboration - and capitalisation in a clinical setting of the many new vistas and opportunities that will arise. As such this research programme brings together a group of world class scientists (physicists, chemists, engineers and computer experts) and clinicians to design, make and test a cutting-edge bedside technology platform which will help doctors in the intensive care unit (ICU) make rapid and accurate diagnoses that would inform therapy and ensure patients get the right treatment, quickly. While we are developing our technology platform with a focus on ICU, it will also be applicable to a wide range of other healthcare situations.

ICU patients suffer high death and disability rates and are responsible for a disproportionate financial burden on the health service. Potentially fatal lung complications are a common problem in ventilated ICU patients and doctors caring for these patients in the ICU face many challenges, often needing to make snap decisions without the information necessary to properly inform those decisions. The technology platform developed in this programme will provide doctors with important information on the state of ICU patients and whether they have infections, inflammation or scarring in their lungs. Currently there are no methods to do this accurately. This information will aid them in making decisions about treatment. A new approach to rapidly diagnose lung complications in ICU would enable doctors to target the correct drugs to the appropriate patients and to withdraw drugs with confidence, with resultant improvement in patient outcomes and major cost efficiencies - thus revolutionising ICU care.

Using advanced fibre optic technology and micro-electronics and new sensor arrays our ground-breaking solution is to create a novel fibre-based probe that can readily be passed into the gas exchanging areas of the lung and blood vessels of ICU patients. The probe will house a variety of special optical fibres, some of which allow clinicians to "view" inside the lung while others will be modified with sensors that can measure important parameters such as oxygen concentration and acidity in both blood and lung. In addition the fibre will deliver tiny amounts (microdoses) of 'smart reagents' that fluorescently detect specific bacteria and other agents that can damage the lung. When integrated together these signals will provide highly specific information about the degree or type of lung damage and the potential causative 'bug' if an infection is suspected. Because of the large amount of information generated and in order to make it easily interpreted by doctors, computing experts will convert these signals into easy-to-understand disease readouts for our clinicians.

Work on the different elements needed to create this technology platform will be undertaken by groups of chemists, physicists, engineers, computer scientists and biologists working at Bath, Heriot Watt and Edinburgh universities. Crucially, this programme will bring these scientific disciplines together in a "hub" where they will work side-by-side, promoting integration of purpose and to ensure that advances are rapidly translated into the clinical setting. This interdisciplinary hub will also provide a fertile training base for new PhD students who will learn the cross-disciplinary skills that will equip them to meet the challenges of translating the current 'revolution' in physical sciences into benefit for UK healthcare.

In summary this project will generate; 1) a new cohort of scientists trained in physical and biological science that have a full appreciation of clinical translational and commercialisation pathways and who are equipped to meet the challenges of converting advances in basic science into healthcare benefit and; 2) a cutting-edge bedside technology platform which will help doctors in the ICU make rapid and accurate diagnoses.

Planned Impact

Our proposed research programme will generate numerous avenues for the realisation of impact:

Patients: FOSIP will provide a unique opportunity for clinicians to rapidly monitor key physiological and pathological events simultaneously in the lungs and blood of critically ill patients in 'real time' at the bedside without the need for cumbersome equipment or ionizing radiation. This will permit rapid 'point-of-care diagnosis and informed decision-making in intensive care units. It will also enable patient stratification for 'personalised' new/expensive drug therapy thereby significantly reducing morbidity and mortality. FOSIP would also be readily applicable to other diseased organs accessible to fibrescopes, particularly the genitourinary tract and the upper and lower gastrointestinal tract.

NHS: Although patient numbers in ICUs are comparatively small, the economic burden is disproportionately huge. Rapid and incisive bedside diagnosis, particularly of specific infections or inflammation/scarring processes would lead to stratification of patient care and tailored prescribing patterns, including the use/non-use of expensive and potentially toxic anti-bacterials. Ultimately this would translate into reduced ventilator dependency and reduced mortality and morbidity with a proportionate economic benefit.

UK PLC: UK Healthcare must reap the dividend of the current 'revolution' in physical sciences. This research programme will deliver new leading-edge multi and cross-disciplinary research in exciting and highly translatable areas of optics, imaging, data analysis and chemistry. Our proposed programme is driven by a clear "healthcare pull" from ICU (with application to diseases in other organs); it fits squarely with EPSRC goals in the Healthcare and Life Sciences sector. Enabling activities through our IRC will create a new generation of scientists, engineers and technologists with a translational agenda and mind-set for the benefit of the UK economy.

Training: A central part of our agenda is to break down traditional 'barriers' between physical and biomedical sciences. The PDRA's will benefit immensely from the interdisciplinary, translational thrust of the programme and the cross-fertilisation that will derive from the 'hub' in work package 6. Moreover, through our PhD students specifically engaged in cross-disciplinary projects we will create a new cadre of scientist who are multi-skilled and equipped to meet the challenges of applying new technologies to healthcare provision in the new era. They will gain a wide variety of both "hard and soft" skills that will be readily applied in a variety of employment sectors.

Industry: All the applicants have major interactions with industry, and most have direct personal experience of spin-off/spin-out companies. As the programme progresses new commercial opportunities will undoubtedly arise in fibre technology, engineering, novel chemical probes, image analysis and computing. When the integrative capacity of the programme is realised and FOSIP is applied to human disease and its models, commercialization prospects in the global healthcare arena will be significant.

General: Our multidisciplinary programme will provide many opportunities for involvement in public engagement and dissemination. Research fellows will participate at the International Science Festivals and become involved in a variety of out-reach activities such as the 'Researchers-in-Residence Programme' which places postgraduate students in local secondary schools allowing the public to benefit, as well as engaging the next generation of scientists.

Publications

10 25 50
 
Title PROTEUS ART EXHIBITION 
Description Ron O'Donnell - Photographs 
Type Of Art Artwork 
Year Produced 2015 
Impact • Proteus Art Exhibition - Introducing Proteus science through contemporary art. (Edinburgh/China) March 2015/ June 2015 Audience: Wider members of the public, academics, patients Engagement methods: Working with a contemporary artist to create portraits of our researchers which allowed dialogue about the specifics of their science research. Impact: High level of interest - changed hearts and minds in terms of who our scientists are and what the science can achieve- reflected in a questionnaire- high levels of satisfaction and desire to learn more. Event in China as sparked interest in examining how science communication can grow and become established in the Chinese culture - work still on going. 
 
Title • Proteus Science Ceilidh: Smart Probes Light Up Science Ceilidh 
Description • Proteus Science Ceilidh: Smart Probes Light Up Science Ceilidh (Edinburgh) December 2015 Audience: Wider members of the public (adult audience) Engagement methods: Dance and Music (using the arts to explain Smart Probe science) Impact: Increased public's appetite for more creative science engagement - learning through fun and accessible methods. More hits on Proteus website/Social Media post event. Feedback suggested participants would attend a similar event. 
Type Of Art Performance (Music, Dance, Drama, etc) 
Year Produced 2015 
Impact • Proteus Science Ceilidh: Smart Probes Light Up Science Ceilidh (Edinburgh) December 2015 Audience: Wider members of the public (adult audience) Engagement methods: Dance and Music (using the arts to explain Smart Probe science) Impact: Increased public's appetite for more creative science engagement - learning through fun and accessible methods. More hits on Proteus website/Social Media post event. Feedback suggested participants would attend a similar event. 
 
Description New world-leading fibres for imaging and sensing - including disposable imaging fibre, Raman fibre (background free), flexible imaging fibres.
New world-leading CMSO SPAD detectors and their integration into systems that are entering clinic to allow a whole new dimension in optical medical imaging.
New world-leading chemical probes and their in-human use - for cancer margins and fibrosis and bacteria.
Major collaborations with industry to develop and push the technology in the area of cancer imaging/detection.
Highly trained staff - that are much in demand. Two PDRA's have won fellowships/gained fully independent academic positions.
Exploitation Route Many elements have gone into clinic. Many elements are being used together and combined for clinical studies - with Phase-II studies on going.

12 Patents filed and we are looking to explore these in spinout ventures and in collaboration with various companies.
Sectors Healthcare

URL http://www.proteus.ac.uk
 
Description Clinical Translation: We have developed a regulatory pathway that has allowed us to carry out first in-human studies (both device and probes). Proteus has, to date, delivered into the clinic a device (VersiColour) and three imaging reagents (Bac- One, Bac-Two and Fib-One) Patients: Proteus is providing unique opportunities for clinicians to rapidly monitor events deep in the lungs of critically ill patients in 'real time' at the bedside. This will permit rapid point-of-care diagnosis and informed decision-making in intensive care units and patient stratification. We are actively involving patients in our programme to increase impact and involve patients in our research ideas and plans. NHS: The economic burden of ICU patients is huge. Rapid and incisive bedside diagnosis, particularly of specific infections would lead to stratification of patient care and tailored prescribing patterns, including the use/non-use of expensive and potentially toxic anti-bacterials. Ultimately this would translate into reduced antibiotic use, reduced ventilator dependency and reduced mortality and morbidity with a proportionate economic benefit. The aim of the Proteus platform is to provide in vivo in situ molecular pathological characterisation of diseased tissues, with an initial focus on the injured and inflamed lung of mechanically ventilated critically ill patients. Critical care is the highest cost area of the modern hospitals with costs of >£3000 per day. In the USA, a staggering 1% of GDP is spent annually in the Intensive Care Unit (ICU) environment. Key goals include delineating infection from sterile inflammation in the lung. Currently no bedside methods exist that are able to delineate pathological processes deep in the human lung in vivo in situ. Hence, the platform offers a disruptive paradigm changing technology.
First Year Of Impact 2017
Sector Healthcare
Impact Types Societal

 
Description American Association for the Advancement of Science Meeting 2018 - Invited to the meeting as a Flagship EPSRC project representing UK science on the main exhibition stage as well as the International Reception. Engagement Methods -Proteus Digital Lung Game - Designed by Proteus team in collaboration with Glasgow Science Centre. Impact: Raised awareness of EPSRC Proteus with UKRI CEO and wider RIUK team. Networked with senior academics, policy makers and US industries. Received media coverage for the project from the BBC.
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
Impact Impact: Raised awareness of EPSRC Proteus with UKRI CEO and wider RIUK team. Engaged with senior academics, policy makers and US industries and wider public. Received media coverage for the project from the BBC.
URL http://www.bbc.co.uk/news/science-environment-43076783
 
Description Awarded The Royal Academy of Engineering Ingenious Grant - (Audience: Scottish Schools (students and teachers) and Research Centre for Teachers continuous Development. Engagement methods: Education tools that describe Proteus biomedical research. Impact: Embed Proteus Circuits! tools into Scottish curriculum to teach 12/13 year old students about bioengineering and its applications around health and wellbeing.
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
Impact Inspire Students to consider STEM subjects and careers. Teach students about biomedical engineering in new engaging ways. bridge gaps between high school teachers and university research. Empower teachers to teach students about cutting edge research. Provide training and skills for researchers to engage widely and with confidence and expertise.
URL https://proteus.ac.uk/public-engagement/ingenious/our-project-circuits/
 
Description House of Lords Science and Technology Committee
Geographic Reach National 
Policy Influence Type Gave evidence to a government review
URL http://www.parliamentlive.tv/Event/Index/3a9d05fd-a47f-411f-8173-5d99a1d53327
 
Description Proteus Showcase Event (Edinburgh) October 2014 - Note none of the options allowed below fit ! An open text box would be more useful !
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Description The Royal Society of Edinburgh AMR (Antimicrobial Resistance) October 2014
Geographic Reach National 
Policy Influence Type Participation in a national consultation
Impact --
 
Description • ICU Engagement Event February 2016 Audience: NHS ICU staff Engagement methods: Hands on demonstrations, posters, written materials Impact: Raise awareness of Proteus Science to end users - strengthened engagement, created possibilities for ongoing dialogue. • ICU Research Nurses Event February 2018 Audience: NHS ICU Research nurses Engagement methods: Hands on demonstrations, posters, written materials Impact: Raise awareness of Proteus Science to research nurses who may use Proteus technology. Introduced nurses to members of the Proteus team, strengthen engagement and interdisciplinary work.
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
Impact --
 
Description • Public and Patient Involvement - Funding Award Received from ACCORD February 2018 Audience: Respiratory Patients (Breathtakers and Breatheasy) Engagement methods: Dialogue sessions with patients, creative story telling workshops Impact: Creation of Proteus research pod at Glasgow science. Work ongoing to develop pilot studies for patient engagement using the Proteus interdisciplinarity model as an engagement framework.
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
Impact --
 
Description • Science and the Parliament (Edinburgh) November 2016 Audience: MPs, Senior Academics, Industry, Healthcare Professionals Engagement methods: Hands on demonstrations, videos, written materials Impact: Raise awareness of Proteus Science, forged a link with Scottish Chief Medical Officer - arranged meeting to visit Proteus labs post event.
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description Accurate, Rapid, Robust and Economical diagnostic technoliogieS for Tuberculosis
Amount € 4,400,000 (EUR)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 01/2020 
End 12/2022
 
Description IRC Next Steps Plus: Photonic Pathogen Theranostics - Point-of-care image guided photonic therapy of bacterial and fungal infection
Amount £1,100,000 (GBP)
Funding ID EP/R018669/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start 04/2019 
End 03/2022
 
Description IRC Next steps funding
Amount £3,900,000 (GBP)
Funding ID EP/R005257/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start 03/2019 
End 02/2023
 
Description MRC CiC (none of the options below re grant type are right/suitable as it is a confidence in concept grant)
Amount £700,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2018 
End 02/2020
 
Description WT/CARB-X (none of the "type of funding" given below are really suitable)
Amount £2,500,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2017 
End 12/2022
 
Description This is an IRC - it is by definition a collaboration 
Organisation Heriot-Watt University
Country United Kingdom 
Sector Academic/University 
PI Contribution The IRC team comprises the Universities of Edinburgh, Heriot Watt and Bath.
Collaborator Contribution Massive collaborations (please see the web site www.proteus.ac.uk)
Impact Please see list of publications/patents/engagement activities on the Proteus web site.
Start Year 2013
 
Description This is an IRC - it is by definition a collaboration 
Organisation University of Bath
Country United Kingdom 
Sector Academic/University 
PI Contribution The IRC team comprises the Universities of Edinburgh, Heriot Watt and Bath.
Collaborator Contribution Massive collaborations (please see the web site www.proteus.ac.uk)
Impact Please see list of publications/patents/engagement activities on the Proteus web site.
Start Year 2013
 
Title - OPTICAL PROBE FOR THROMBIN 
Description OPTICAL PROBE FOR THROMBIN 
IP Reference WO2016151297 
Protection Patent application published
Year Protection Granted
Licensed Commercial In Confidence
Impact Confidential
 
Title A SENSING STRUCTURE AND METHOD OF FORMING A SENSING STRUCTURE 
Description A SENSING STRUCTURE AND METHOD OF FORMING A SENSING STRUCTURE 
IP Reference WO2017203272 
Protection Patent application published
Year Protection Granted
Licensed Commercial In Confidence
Impact Confidential
 
Title ENDOSCOPIC IMAGING APPARATUS AND METHOD 
Description ENDOSCOPIC IMAGING APPARATUS AND METHOD 
IP Reference WO2017174998 
Protection Patent application published
Year Protection Granted
Licensed Commercial In Confidence
Impact Confidentail
 
Title FLUORESCENT POLYBRANCHED PROBES FOR DETECTING BACTERIA AND/OR FUNGI IN VITRO AND IN VIVO 
Description FLUORESCENT POLYBRANCHED PROBES FOR DETECTING BACTERIA AND/OR FUNGI IN VITRO AND IN VIVO 
IP Reference WO2016075484 
Protection Patent application published
Year Protection Granted
Licensed Commercial In Confidence
Impact Confidential
 
Title FRAME SELECTION IN MEDICAL IMAGE DATA 
Description FRAME SELECTION IN MEDICAL IMAGE DATA 
IP Reference WO2017149310 
Protection Patent application published
Year Protection Granted
Licensed Commercial In Confidence
Impact Confidential
 
Title FRET MOLECULAR PROBES WITH CLEAVABLE LINKERS FOR DETECTING BACTERIA AND/OR FUNGI IN VITRO AND IN VIVO 
Description FRET MOLECULAR PROBES WITH CLEAVABLE LINKERS FOR DETECTING BACTERIA AND/OR FUNGI IN VITRO AND IN VIVO 
IP Reference WO2016075481 
Protection Patent application published
Year Protection Granted
Licensed Commercial In Confidence
Impact Confidential
 
Title Molecular probes for detecting gram-negative bacteria in vitro and in vivo 
Description Molecular probes for detecting gram-negative bacteria in vitro and in vivo 
IP Reference WO2016075483 
Protection Patent application published
Year Protection Granted
Licensed Commercial In Confidence
Impact Confidential
 
Title OPTICAL IMAGING PROBES 
Description OPTICAL IMAGING PROBES 
IP Reference WO2012136958 
Protection Patent granted
Year Protection Granted 2017
Licensed Commercial In Confidence
Impact Confidential
 
Title OPTICAL PROBES FOR MATRIX METALLOPROTEINASES (the question below is wrong - protection is not received from a filing or if the PCT is published it has to go through national phases - and I cannot add this unless I put a date). 
Description OPTICAL PROBES FOR MATRIX METALLOPROTEINASES 
IP Reference WO2016151299 
Protection Patent application published
Year Protection Granted 2016
Licensed Commercial In Confidence
Impact confidential
 
Title OPTICAL SYSTEM AND METHOD 
Description A system comprises a waveguide apparatus comprising a plurality of input waveguides, a multimode waveguide, and a guided-wave transition coupling the plurality of input waveguides to the multimode waveguide. The system further comprises at least one light source configured to excite in turn each of a plurality of the input waveguides, or each of a plurality of combinations of the input waveguides, thereby generating a plurality of different light patterns in turn at an output of the waveguide apparatus. The waveguide apparatus is configured to direct each of the plurality of different light patterns to a target region. The system further comprises at least one detector configured to detect light transmitted, reflected or emitted from the target region in response to each of the different light patterns, and to output signals representing the detected light. 
IP Reference WO2018203088 
Protection Patent application published
Year Protection Granted 2018
Licensed Commercial In Confidence
Impact Confidential
 
Title SERS PROBE COMPRISING A DUAL-CORE OPTICAL FIBER AND A SPACER ONTO WHICH SERS-ACTIVE NANOPARTICLES ARE ATTACHED 
Description SERS PROBE COMPRISING A DUAL-CORE OPTICAL FIBER AND A SPACER ONTO WHICH SERS-ACTIVE NANOPARTICLES ARE ATTACHED 
IP Reference WO2017158331 
Protection Patent application published
Year Protection Granted
Licensed Commercial In Confidence
Impact Confidential
 
Title Bac-II 
Description Critically ill patients are often ventilated in dedicated critical care units to provide respiratory support. Despite best practice patients can often develop a condition called adult respiratory distress syndrome (ARDS), which is characterised by deterioration in their respiratory function, and changes on chest x-ray. The correct management for ARDS is identifying the underlying condition causing the deterioration and identifying appropriate targeted therapy. One such cause is pneumonia, caused by a bacterial infection in the lungs of a ventilated patient. The patients may have been ventilated due to pneumonia but they may also develop pneumonia whilst ventilated. Ventilator associated pneumonia (VAP) has significant mortality. Despite all the clinical and laboratory data at the investigators' disposal there remains great difficulty in the accurate diagnosis of pneumonia and therefore treatment is often given empirically. Therefore, there is an urgent clinical need for accurate methods to diagnose the presence of bacteria deep in the lung in ventilated critically ill patients. As such, the investigating team have developed and synthesised an imaging agent called BAC TWO. BAC TWO will be instilled directly into the lungs of 12 patients to assess whether it can label gram-negative bacteria in the human lung. 
Type Diagnostic Tool - Imaging
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2016
Development Status Under active development/distribution
Clinical Trial? Yes
UKCRN/ISCTN Identifier XX
Impact Critically ill patients are often ventilated in dedicated critical care units to provide respiratory support. Despite best practice patients can often develop a condition called adult respiratory distress syndrome (ARDS), which is characterised by deterioration in their respiratory function, and changes on chest x-ray. The correct management for ARDS is identifying the underlying condition causing the deterioration and identifying appropriate targeted therapy. One such cause is pneumonia, caused by a bacterial infection in the lungs of a ventilated patient. The patients may have been ventilated due to pneumonia but they may also develop pneumonia whilst ventilated. Ventilator associated pneumonia (VAP) has significant mortality. Despite all the clinical and laboratory data at the investigators' disposal there remains great difficulty in the accurate diagnosis of pneumonia and therefore treatment is often given empirically. Therefore, there is an urgent clinical need for accurate methods to diagnose the presence of bacteria deep in the lung in ventilated critically ill patients. As such, the investigating team have developed and synthesised an imaging agent called BAC TWO. BAC TWO will be instilled directly into the lungs of 12 patients to assess whether it can label gram-negative bacteria in the human lung. 
URL https://clinicaltrials.gov/ct2/show/NCT02491164?term=NCT02491164&rank=1
 
Title Exploratory clinical study of intrapulmonary microdosing of the BACterial detection probe (BAC ONE) 
Description Critically ill patients are often ventilated in dedicated critical care units to provide respiratory support. Despite best practice patients can often develop a condition called adult respiratory distress syndrome (ARDS), which is characterised by deterioration in their respiratory function, and changes on chest x-ray. The correct management for ARDS is identifying the underlying condition causing the deterioration and identifying appropriate targeted therapy. One such cause is pneumonia, caused by a bacterial infection in the lungs of a ventilated patient. The patients may have been ventilated due to pneumonia but they may also develop pneumonia whilst ventilated. Ventilator associated pneumonia (VAP) has significant mortality. Despite all the clinical and laboratory data at the investigators' disposal there remains great difficulty in the accurate diagnosis of pneumonia and therefore treatment is often given empirically. Therefore, there is an urgent clinical need for accurate methods to diagnose the presence of bacteria deep in the lung in ventilated critically ill patients. As such, the investigating team have developed and synthesised an imaging agent called BAC ONE. BAC ONE will be instilled directly into the lungs of 12 patients (with and without lung infection) to assess whether it can label bacteria in the human lung. 
Type Diagnostic Tool - Imaging
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2018
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Critically ill patients are often ventilated in dedicated critical care units to provide respiratory support. Despite best practice patients can often develop a condition called adult respiratory distress syndrome (ARDS), which is characterised by deterioration in their respiratory function, and changes on chest x-ray. The correct management for ARDS is identifying the underlying condition causing the deterioration and identifying appropriate targeted therapy. One such cause is pneumonia, caused by a bacterial infection in the lungs of a ventilated patient. The patients may have been ventilated due to pneumonia but they may also develop pneumonia whilst ventilated. Ventilator associated pneumonia (VAP) has significant mortality. Despite all the clinical and laboratory data at the investigators' disposal there remains great difficulty in the accurate diagnosis of pneumonia and therefore treatment is often given empirically. Therefore, there is an urgent clinical need for accurate methods to diagnose the presence of bacteria deep in the lung in ventilated critically ill patients. As such, the investigating team have developed and synthesised an imaging agent called BAC ONE. BAC ONE will be instilled directly into the lungs of 12 patients (with and without lung infection) to assess whether it can label bacteria in the human lung. 
URL https://clinicaltrials.gov/ct2/show/NCT02558062?term=NCT02558062&rank=1
 
Title Exploratory study to optically visualise activated neutrophils and the proto-oncogene, c-MET, in lung masses using DUAL colour fibre-based endomicroscopy (DUAL) 
Description Lung cancer is currently a major health problem in the UK. Despite being one of the most common cancers, lung cancer has a poor prognosis compared to other types of cancer and is the leading cause of cancer death in the world. As opposed to other organs, the lung is highly susceptible to inflammatory insults, for example from bacterial infection-induced and tobacco-induced inflammation. It has long been known that the cellular microenvironment that nurtures tumour growth and development is linked to sites of chronic inflammation but molecular insights into how external inflammation boosts or inhibits cancer in the lungs remains unclear. This study aims to directly visualise the expression of a well known marker of cancerous tissue, c-MET, and the activity of neutrophils in human lung cancer in vivo in situ using fibre-based endomicroscopy. 
Type Diagnostic Tool - Imaging
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2018
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Lung cancer is currently a major health problem in the UK. Despite being one of the most common cancers, lung cancer has a poor prognosis compared to other types of cancer and is the leading cause of cancer death in the world. As opposed to other organs, the lung is highly susceptible to inflammatory insults, for example from bacterial infection-induced and tobacco-induced inflammation. It has long been known that the cellular microenvironment that nurtures tumour growth and development is linked to sites of chronic inflammation but molecular insights into how external inflammation boosts or inhibits cancer in the lungs remains unclear. This study aims to directly visualise the expression of a well known marker of cancerous tissue, c-MET, and the activity of neutrophils in human lung cancer in vivo in situ using fibre-based endomicroscopy. 
URL https://clinicaltrials.gov/ct2/show/NCT02676050?term=NCT02676050&rank=1
 
Title FIB-ONE 
Description Brief Summary: While the process of fibrosis is essential for normal wound healing, an excessive and uncontrolled 'fibrotic' response can result in impaired tissue structure and function. In other words, affected 'fibrotic' tissues are unable to heal back to normal and therefore don't work as effectively as they normally would. In the case of the lung, fibrosis can occur across large parts of the lung such as in conditions like Idiopathic Pulmonary Fibrosis (IPF) and sarcoidosis or it can occur in much smaller patches such as around the borders of some lung tumours. At the moment the investigators don't fully understand the mechanisms of fibrosis and so therefore cannot monitor or treat these conditions as effectively as the investigators could. Despite the significant global financial burden of these diseases, treatment options are very limited and monitoring of disease progression remains a real challenge. In an effort to address this problem, the research team have designed and synthesised an imaging agent (FIB ONE) that can detect fibrosis in the lung. FIB ONE will be used at very low concentrations in patients with a lung condition characterised by excessive activity of the fibroproliferative pathway either scheduled for a routine bronchoscopy or elective surgery. FIB ONE will be administered directly into the lungs during a bronchoscopy procedure and images of the lungs will be analysed. As part of this study, the research team's novel endomicroscopy detection system will be compared to equipment that is routinely used in the NHS when imaging the FIB ONE probe. 
Type Diagnostic Tool - Imaging
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2017
Development Status Under active development/distribution
Clinical Trial? Yes
UKCRN/ISCTN Identifier XX
Impact Brief Summary: While the process of fibrosis is essential for normal wound healing, an excessive and uncontrolled 'fibrotic' response can result in impaired tissue structure and function. In other words, affected 'fibrotic' tissues are unable to heal back to normal and therefore don't work as effectively as they normally would. In the case of the lung, fibrosis can occur across large parts of the lung such as in conditions like Idiopathic Pulmonary Fibrosis (IPF) and sarcoidosis or it can occur in much smaller patches such as around the borders of some lung tumours. At the moment the investigators don't fully understand the mechanisms of fibrosis and so therefore cannot monitor or treat these conditions as effectively as the investigators could. Despite the significant global financial burden of these diseases, treatment options are very limited and monitoring of disease progression remains a real challenge. In an effort to address this problem, the research team have designed and synthesised an imaging agent (FIB ONE) that can detect fibrosis in the lung. FIB ONE will be used at very low concentrations in patients with a lung condition characterised by excessive activity of the fibroproliferative pathway either scheduled for a routine bronchoscopy or elective surgery. FIB ONE will be administered directly into the lungs during a bronchoscopy procedure and images of the lungs will be analysed. As part of this study, the research team's novel endomicroscopy detection system will be compared to equipment that is routinely used in the NHS when imaging the FIB ONE probe. 
URL https://clinicaltrials.gov/ct2/show/NCT02604862?term=NCT02604862&rank=1
 
Title SNAP-IT (NAP IN ICU) 
Description Critically ill patients often succumb to acute respiratory disease (rapidly developing disease affecting the lungs). The lungs are the commonest organ to fail and require support in the intensive care environment. However, no accurate methods exist that can be used at the bedside to tell what is causing deterioration in a person's lungs. There are various examples of acute respiratory diseases that can occur as a result of numerous different causes, have a high risk of death and cannot be treated easily with drugs. When trying to accurately diagnose and classify these lung diseases there is a risk that the type of respiratory disease is misdiagnosed, missed or the level of severity is not captured. By using the field of optical molecular imaging and employing novel techniques and technologies, the investigators hope to demonstrate here that a bespoke chemical probe administered in micro doses (tiny doses) directly into the distal lung can rapidly and accurately detect activated neutrophils (cells of the immune system that are implicated in the development of these severe conditions), and so work towards a bedside test which could be used to diagnose, monitor and classify the disease in patients who are critically ill in the future. The population for this study are in intensive care where patients are normally intubated (have a breathing tube) due to the severity of their illness, this may be because of respiratory problems or respiratory problems can rapidly develop. Participants will have the chemical probe administered into their lungs and pictures taken through the tube already in place. As this probe lights up when it comes into contact with neutrophils the investigators will be able to tell if neutrophils are present. This will inform a larger study in which it's hoped that the method can be used to inform clinical decisions. The first procedure will take place within two days of initiation of mechanical ventilation and the direct contact with the study team will be completed within nine days. 
Type Diagnostic Tool - Imaging
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2017
Development Status Under active development/distribution
Clinical Trial? Yes
UKCRN/ISCTN Identifier XX
Impact Critically ill patients often succumb to acute respiratory disease (rapidly developing disease affecting the lungs). The lungs are the commonest organ to fail and require support in the intensive care environment. However, no accurate methods exist that can be used at the bedside to tell what is causing deterioration in a person's lungs. There are various examples of acute respiratory diseases that can occur as a result of numerous different causes, have a high risk of death and cannot be treated easily with drugs. When trying to accurately diagnose and classify these lung diseases there is a risk that the type of respiratory disease is misdiagnosed, missed or the level of severity is not captured. By using the field of optical molecular imaging and employing novel techniques and technologies, the investigators hope to demonstrate here that a bespoke chemical probe administered in micro doses (tiny doses) directly into the distal lung can rapidly and accurately detect activated neutrophils (cells of the immune system that are implicated in the development of these severe conditions), and so work towards a bedside test which could be used to diagnose, monitor and classify the disease in patients who are critically ill in the future. The population for this study are in intensive care where patients are normally intubated (have a breathing tube) due to the severity of their illness, this may be because of respiratory problems or respiratory problems can rapidly develop. Participants will have the chemical probe administered into their lungs and pictures taken through the tube already in place. As this probe lights up when it comes into contact with neutrophils the investigators will be able to tell if neutrophils are present. This will inform a larger study in which it's hoped that the method can be used to inform clinical decisions. The first procedure will take place within two days of initiation of mechanical ventilation and the direct contact with the study team will be completed within nine days. 
URL https://clinicaltrials.gov/ct2/show/NCT02804854?term=NCT02804854&rank=1
 
Description AAAS Meeting 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact AAAS Meeting 2019 - Invited to the meeting as a Flagship EPSRC project representing UK science on the main exhibition stage as well as the International Reception.
Feb 2019
Audience: American Academics, Members of Congress, American Industries, RIUK team lead by Sir Mark Walport (CEO) World Media Teams, Global stakeholders (academics, policy makers) students and wider publics
Engagement methods: Proteus Technology Versicolour
Impact: Raised awareness of EPSRC Proteus with UKRI CEO and wider RIUK team. Networked with senior academics, policy makers and US industries. Created new collaborations with industrial partners
Year(s) Of Engagement Activity 2019
URL https://www.ukri.org/aaas/
 
Description Development of an ICU Patient and Public Involvement Group 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact Public and Patient Involvement -I CU PPI GROUP
March 2018
Audience: ICU Patients and families
Engagement methods: Dialogue sessions with patients, partnership building activities, developing PPI projects
Impact: Creation of Edinburgh's first ICU PPI group, working with the Critical Care Team in Edinburgh and nationally with ICU Steps - has allowed ICU patients to take part in Proteus engagement activities and has strengthen Proteus' PPI portfolio
Year(s) Of Engagement Activity 2018
URL https://www.ed.ac.uk/clinical-sciences/divisionpgdi/anaesthesia/news-views/icusteps-patient-and-fami...
 
Description EPSRC Our Health - Dr Henk Mulder Visit (Science Shop Expert, The University of Groningen) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact EPSRC Our Health - Dr Henk Mulder Visit (Science Shop Expert, The University of Groningen)
April 2018
Audience: Local community, patient groups, undergraduates/postgraduates, academics and Public Engagement Professionals
Engagement methods: Presentation and workshop
Impact: Dr Henk Mulder's visit for part of a University wide consultation around the Science Shop model for community/patient engagement and resulted in the funding and launch of Our Health
Year(s) Of Engagement Activity 2018
 
Description EPSRC Our Health - The First UK Interdisciplinary Science Shop 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact EPSRC Our Health - The First UK Interdisciplinary Science Shop
June 2018
Audience: Local community, patient groups, undergraduates/postgraduates, academics and Public Engagement professionals
Engagement methods: Community based research projects around Health and well being
Impact: EPSRC Our Health (within first 6 months of launch) has created national and international impact. Our Health was selected to host the Experienced Practice Learning Exchange for international delegates as part of The National Co ordinating Centre's National ENGAGE 2018 Conference.
EPSRC Our Health has also been asked to work in partnership with UKRI International PE team to develop global projects for Our Health. Our Health has impacted the local community by creating new knowledge around health and well being with community partners.
Year(s) Of Engagement Activity 2018
URL https://proteus.ac.uk/public-engagement/developing-community-partnerships/our-health/about-our-healt...
 
Description Living Knowledge 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Living Knowledge 2018 - Invited as a speaker to the Living Knowledge Confrenec (Budapest) to present EPSRC Our Health and share best practice around this new Interdisciplinary model of a science shop
July 2018
Audience: International Public Engagement Delegates and Community partners
Engagement methods: Workshops, presentations and visits to local communities to talk with people about their involvement in PE.
Impact: EPSRC Our Health is now established with in the European community and is part of a wider network and a leader in the field of interdisciplinary community research
Year(s) Of Engagement Activity 2018
URL https://www.livingknowledge.org/lk8/
 
Description Proteus Partnership with Msc Science Communication Programme 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Proteus Partnership with Msc Science Communication Programme
2018
Audience: Eight Science Communication Master Students work with Proteus each year engaging wider publics and community partners.
Engagement methods: science writing, activity based presentations, dialogic workshops and creative co inquiry.
Impact: developed a community of public engagement practice throughout the university and with local universities. Sharing of best practice, improving quality and impact of public engagement work. Work created by students have promoted and raised the profile of Proteus across a wide range of project stakeholders.
Year(s) Of Engagement Activity 2018
 
Description Proteus Public Engagement (PE) Strategic Influence 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Proteus Public Engagement (PE) Strategic Influence - Proteus represented at the Strategic PE Group, The University of Edinburgh
March 2018
Audience: Senior colleagues working within PE and members of the wider public, The University of Edinburgh (UoE)
Engagement methods: Committee discussions, development of UoE PE strategy
Impact: Proteus PE influences the strategic direction of PE for The University of Edinburgh
Year(s) Of Engagement Activity 2018
URL https://www.ed.ac.uk/institute-academic-development/research-roles/public-engagement/pe-strategy
 
Description Science at Heriot Watt 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Science at Heriot Watt 2018 (Heriot Watt University)
April 2018
Audience: Wider Public
Engagement methods: Hands on demonstrations, activities and storytelling
Impact: Raise awareness of Proteus Science with family audience. Strengthened links with Heriot Watt University.
Year(s) Of Engagement Activity 2018
 
Description The Edinburgh International Science Festival (Edinburgh) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact The Edinburgh International Science Festival (Edinburgh)
April 2018
Audience: Wider Public
Engagement methods: Hands on demonstrations, activities and storytelling
Impact: Raised awareness of Proteus Science with family audiences. Created interest amongst researcher working in infectious diseases in Roslin centre - formed new collaboration with Dr Kenneth Ballie around PE activities
Year(s) Of Engagement Activity 2018
 
Description The International Edinburgh Book Festival - EPSRC Proteus/ EPSRC Our Health 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact The International Edinburgh Book Festival
August 2018
Audience: Wider Public
Engagement methods: Hands on demonstrations and research art exhibition. Our Health students and community partners formed a choir and sang.
Impact: Principal of The University of Edinburgh attended and gave strong support for Proteus/Our Health. As a consequence of this event the The University of Edinburgh, Proteus/Our Health and The International Edinburgh Book Festival have agreed to work together on further PE activities
Year(s) Of Engagement Activity 2018